ArticleArthritis & rheumatology (Hoboken, N.J.)2015
Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- The 2024 British Society for Rheumatology guideline for management of systemic sclerosis.Rheumatology (Oxford, England) · 2024Guideline
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.Arthritis care & research · 2017Pooled it
- Recent Advances in Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease: Clinical Relevance and Therapeutic Perspectives.Life (Basel, Switzerland) · 2026Review
- Clinical Associations of Anti-RNPC3 Autoantibodies in Mixed Connective Tissue Disease.ACR open rheumatology · 2026Article
- Development of a Personalized Visualization and Analysis Tool to Improve Clinical Care in Complex Multisystem Diseases With Application to Scleroderma.Arthritis care & research · 2026Article
- Scleroderma-Like Skin Changes and Multifocal Muscle Thickening in a Patient with Diffuse Large B-Cell Lymphoma: A Case Report.Cancer management and research · 2026Article
- The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort.Therapeutic advances in musculoskeletal disease · 2026Article
- The clinical utility of autoantibodies in systemic sclerosis: a review with a focus on cohort differences and standardization.Frontiers in immunology · 2025Review
- Evaluation of malignancy risk in patients with SSc by autoantibody profile: a systematic review with meta-analysis.Rheumatology advances in practice · 2025Review
- Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis.RMD open · 2024Article
- Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis.Seminars in arthritis and rheumatism · 2024Article
- Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Case report: Systemic sclerosis during neoadjuvant therapy for breast cancer in a 59-year-old woman.Frontiers in immunology · 2024Review
- Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases.RMD open · 2023Article
- Association between anti-SSSCA1 antibodies and cancer in systemic sclerosis.Rheumatology (Oxford, England) · 2023Article
- Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.Clinical reviews in allergy & immunology · 2023Article
- Preventative Care in Scleroderma: What Is the Best Approach to Bone Health and Cancer Screening?Rheumatic diseases clinics of North America · 2023Review
- Article
- Systemic Sclerosis Association with Malignancy.Clinical reviews in allergy & immunology · 2022Review
- Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis.Clinical reviews in allergy & immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveWe previously reported a contemporaneous onset of cancer and scleroderma in patients with anti-RNA polymerase III antibodies, and we identified a biologic link between cancer and scleroderma. This investigation was designed to further evaluate whether autoantibody status and other characteristics are associated with cancer and a clustering of cancer with scleroderma onset.
methodsLogistic regression analysis was performed to assess the relationship of 2 outcomes, cancer (model 1) and a short (±2 years) cancer-scleroderma interval (model 2), with autoantibody status and scleroderma covariates.
resultsOf 1,044 scleroderma patients, 168 (16.1%) had cancer. In the adjusted model 1, only older age at scleroderma onset (odds ratio 1.04 [95% confidence interval 1.02-1.05]) and white race (odds ratio 2.71 [95% confidence interval 1.22-6.04]) were significantly associated with an increased overall risk of cancer. In the adjusted model 2, only anti-RNA polymerase III positivity (odds ratio 5.08 [95% confidence interval 1.60-16.1]) and older age at scleroderma onset (odds ratio 1.04 [95% confidence interval 1.00-1.08]) were significantly associated with a short cancer-scleroderma interval. While anti-RNA polymerase III positivity was associated with a short cancer-scleroderma interval independent of age at scleroderma onset, the cancer-scleroderma interval shortened with older age at scleroderma onset in other antibody groups (Spearman's correlation P < 0.05), particularly among patients with anti-topoisomerase I antibodies and patients who were negative for anticentromere, anti-topoisomerase I, and anti-RNA polymerase III antibodies.
conclusionIncreased age at scleroderma onset is strongly associated with cancer risk overall. While anti-RNA polymerase III status is an independent marker of coincident cancer and scleroderma at any age, a clustering of cancer with scleroderma is also seen in patients with anti-topoisomerase I and other autoantibody specificities who develop scleroderma at older ages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.